BR112017005128A2 - inibidores de histona desmetilase - Google Patents
inibidores de histona desmetilaseInfo
- Publication number
- BR112017005128A2 BR112017005128A2 BR112017005128A BR112017005128A BR112017005128A2 BR 112017005128 A2 BR112017005128 A2 BR 112017005128A2 BR 112017005128 A BR112017005128 A BR 112017005128A BR 112017005128 A BR112017005128 A BR 112017005128A BR 112017005128 A2 BR112017005128 A2 BR 112017005128A2
- Authority
- BR
- Brazil
- Prior art keywords
- histone demethylase
- demethylase inhibitors
- inhibitors
- histone
- demethylase
- Prior art date
Links
- 102000008157 Histone Demethylases Human genes 0.000 title 1
- 108010074870 Histone Demethylases Proteins 0.000 title 1
- 239000003112 inhibitor Substances 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4192—1,2,3-Triazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201462051268P | 2014-09-16 | 2014-09-16 | |
| PCT/US2015/050289 WO2016044342A1 (en) | 2014-09-16 | 2015-09-15 | Histone demethylase inhibitors |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BR112017005128A2 true BR112017005128A2 (pt) | 2018-07-31 |
Family
ID=55533770
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BR112017005128A BR112017005128A2 (pt) | 2014-09-16 | 2015-09-15 | inibidores de histona desmetilase |
Country Status (17)
| Country | Link |
|---|---|
| US (2) | US9676770B2 (enExample) |
| EP (1) | EP3193881B1 (enExample) |
| JP (1) | JP6660060B2 (enExample) |
| KR (1) | KR20170048590A (enExample) |
| CN (1) | CN107073006A (enExample) |
| AU (1) | AU2015317904A1 (enExample) |
| BR (1) | BR112017005128A2 (enExample) |
| CA (1) | CA2961525A1 (enExample) |
| CL (1) | CL2017000643A1 (enExample) |
| CO (1) | CO2017002772A2 (enExample) |
| EA (1) | EA201790502A1 (enExample) |
| EC (1) | ECSP17020172A (enExample) |
| ES (1) | ES2911292T3 (enExample) |
| IL (1) | IL251103A0 (enExample) |
| MX (1) | MX2017003464A (enExample) |
| SG (1) | SG11201702108PA (enExample) |
| WO (1) | WO2016044342A1 (enExample) |
Families Citing this family (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2903081A1 (en) | 2013-03-14 | 2014-09-25 | Quanticel Pharmaceuticals, Inc. | Histone demethylase inhibitors |
| US9896436B2 (en) | 2014-09-16 | 2018-02-20 | Celgene Quanticel Research, Inc. | Histone demethylase inhibitors |
| MX2017003464A (es) | 2014-09-16 | 2017-07-13 | Celgene Quanticel Res Inc | Inhibidores de histona desmetilasa. |
| WO2016130501A1 (en) | 2015-02-09 | 2016-08-18 | Incyte Corporation | Aza-heteroaryl compounds as pi3k-gamma inhibitors |
| US10065963B2 (en) | 2015-11-06 | 2018-09-04 | Incyte Corporation | Heterocyclic compounds as PI3K-γ inhibitors |
| ES2995198T3 (en) * | 2016-01-05 | 2025-02-07 | Incyte Corp | Pyridine compounds as pi3k-gamma inhibitors |
| WO2017161033A1 (en) | 2016-03-15 | 2017-09-21 | Celgene Quanticel Research, Inc. | Histone demethylase inhibitors |
| US10150754B2 (en) * | 2016-04-19 | 2018-12-11 | Celgene Quanticel Research, Inc. | Histone demethylase inhibitors |
| AR108875A1 (es) | 2016-06-24 | 2018-10-03 | Incyte Corp | COMPUESTOS HETEROCÍCLICOS COMO INHIBIDORES DE PI3K-g |
| MD3697789T2 (ro) | 2017-10-18 | 2022-02-28 | Incyte Corp | Derivați imidazol condensați substituiți cu grupări hidroxi terțiare ca inhibitori PI3K-GAMA |
| CR20250050A (es) | 2018-09-05 | 2025-03-19 | Incyte Corp | Formas cristalinas de un inhibidor de fosfoinositida 3–quinasa (pi3k) (divisional 2021-0165) |
| CN111116571B (zh) * | 2019-12-27 | 2022-07-12 | 吉首大学 | 含恶唑及三唑双杂环的化合物及其制备与应用方法 |
Family Cites Families (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1058549A4 (en) | 1998-12-23 | 2003-11-12 | Bristol Myers Squibb Pharma Co | FACTOR Xa OR THROMBIN INHIBITORS |
| PL366114A1 (en) | 2000-10-26 | 2005-01-24 | Tularik Inc. | Antiinflammation agents |
| GB0217780D0 (en) | 2002-07-31 | 2002-09-11 | Glaxo Group Ltd | Compounds |
| US20040127733A1 (en) | 2002-10-31 | 2004-07-01 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | New beta-agonists, processes for preparing them and their use as pharmaceutical compositions |
| DE102004021779A1 (de) | 2004-04-30 | 2005-11-24 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Neue Beta-Agonisten, Verfahren zu deren Herstellung und deren Verwendung als Arzneimittel |
| CA2632444A1 (en) | 2005-12-19 | 2007-06-28 | Boehringer Ingelheim International Gmbh | Use of aminoalcohol derivatives for the treatment of overactive bladder |
| EP2205589B1 (en) | 2007-10-03 | 2011-03-23 | Vertex Pharmaceuticals Incorporated | C-met protein kinase inhibitors |
| DE102009019962A1 (de) | 2009-05-05 | 2010-11-11 | Merck Patent Gmbh | 3-([1,2,3]Triazol-4-yl)-pyrrolo[2,3-b]pyridinderivate |
| EP2499139B1 (en) | 2009-11-10 | 2013-12-11 | Pfizer Inc | N1-pyrazolospiroketone acetyl-coa carboxylase inhibitors |
| KR101781663B1 (ko) | 2010-01-13 | 2017-09-25 | 템페로 파마슈티칼즈, 인크. | 히스톤 데아세틸라제 효소를 억제하기 위한 화합물 및 이를 제조하는 방법 |
| MX2015007205A (es) | 2012-12-06 | 2016-03-31 | Quanticel Pharmaceuticals Inc | Inhibidores de la desmetilasa de histona. |
| CA2903081A1 (en) | 2013-03-14 | 2014-09-25 | Quanticel Pharmaceuticals, Inc. | Histone demethylase inhibitors |
| WO2016007722A1 (en) | 2014-07-10 | 2016-01-14 | Incyte Corporation | Triazolopyridines and triazolopyrazines as lsd1 inhibitors |
| MX2017003464A (es) | 2014-09-16 | 2017-07-13 | Celgene Quanticel Res Inc | Inhibidores de histona desmetilasa. |
| US9896436B2 (en) * | 2014-09-16 | 2018-02-20 | Celgene Quanticel Research, Inc. | Histone demethylase inhibitors |
-
2015
- 2015-09-15 MX MX2017003464A patent/MX2017003464A/es unknown
- 2015-09-15 JP JP2017514411A patent/JP6660060B2/ja not_active Expired - Fee Related
- 2015-09-15 EA EA201790502A patent/EA201790502A1/ru unknown
- 2015-09-15 EP EP15842092.7A patent/EP3193881B1/en not_active Not-in-force
- 2015-09-15 US US14/855,269 patent/US9676770B2/en active Active
- 2015-09-15 CN CN201580060763.8A patent/CN107073006A/zh active Pending
- 2015-09-15 BR BR112017005128A patent/BR112017005128A2/pt not_active Application Discontinuation
- 2015-09-15 AU AU2015317904A patent/AU2015317904A1/en not_active Abandoned
- 2015-09-15 KR KR1020177009901A patent/KR20170048590A/ko not_active Withdrawn
- 2015-09-15 ES ES15842092T patent/ES2911292T3/es active Active
- 2015-09-15 CA CA2961525A patent/CA2961525A1/en not_active Abandoned
- 2015-09-15 WO PCT/US2015/050289 patent/WO2016044342A1/en not_active Ceased
- 2015-09-15 SG SG11201702108PA patent/SG11201702108PA/en unknown
-
2017
- 2017-03-12 IL IL251103A patent/IL251103A0/en unknown
- 2017-03-16 CL CL2017000643A patent/CL2017000643A1/es unknown
- 2017-03-23 CO CONC2017/0002772A patent/CO2017002772A2/es unknown
- 2017-03-31 EC ECIEPI201720172A patent/ECSP17020172A/es unknown
- 2017-05-05 US US15/588,495 patent/US10071984B2/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| IL251103A0 (en) | 2017-04-30 |
| US20160108033A1 (en) | 2016-04-21 |
| WO2016044342A1 (en) | 2016-03-24 |
| US10071984B2 (en) | 2018-09-11 |
| EA201790502A1 (ru) | 2017-10-31 |
| KR20170048590A (ko) | 2017-05-08 |
| CA2961525A1 (en) | 2016-03-24 |
| AU2015317904A1 (en) | 2017-04-06 |
| US20170240529A1 (en) | 2017-08-24 |
| JP6660060B2 (ja) | 2020-03-04 |
| CO2017002772A2 (es) | 2017-06-09 |
| EP3193881A1 (en) | 2017-07-26 |
| EP3193881A4 (en) | 2018-02-21 |
| ECSP17020172A (es) | 2017-05-31 |
| MX2017003464A (es) | 2017-07-13 |
| CL2017000643A1 (es) | 2017-12-01 |
| ES2911292T3 (es) | 2022-05-18 |
| CN107073006A (zh) | 2017-08-18 |
| EP3193881B1 (en) | 2022-02-09 |
| SG11201702108PA (en) | 2017-04-27 |
| US9676770B2 (en) | 2017-06-13 |
| JP2017527590A (ja) | 2017-09-21 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EP3541932A4 (en) | INHIBITORS OF CRISPR-CAS9 | |
| BR112016030367A2 (pt) | inibidores de histona desmetilase | |
| BR112017004334A2 (pt) | inibidores de desmetilase específica de lisina-1. | |
| BR112017000043A2 (pt) | inibidores da desmetilase específica de lisina-1 | |
| HUE042335T2 (hu) | ROR-gamma dihidropirrolopiridin inhibitorai | |
| LT3303334T (lt) | Tirozinkinazės inhibitoriai | |
| CL2016002736A1 (es) | Inhibidores de demetilasa-1 específico de lisina | |
| DK3442972T3 (da) | Bromdomænehæmmere | |
| PT3105226T (pt) | Ciclopropilaminas como inibidores de lsd1 | |
| PT2970211T (pt) | Inibidores de histona demetilase | |
| LT3319959T (lt) | Histono deacetilazės hetero-halogeno inhibitoriai | |
| EP3313828A4 (en) | METALLO-BETA-Lactamase INHIBITORS | |
| CU20160125A7 (es) | Inhibidores de diacilglicerol aciltransferasa 2 | |
| BR112017005128A2 (pt) | inibidores de histona desmetilase | |
| DK3341379T3 (da) | EZH2-hæmmere | |
| DK3186242T3 (da) | Alfa-amino-beta-carboxymuconsyre-semialdehyd-decarboxylasehæmmere | |
| IL251179A0 (en) | Histone demethylase inhibitors | |
| DK3114120T3 (da) | Tetrazolon-substituerede dihydropyridinon-mgat2-hæmmere | |
| MA43367A (fr) | Inhibiteurs de métallo-bêta-lactamases | |
| IL251184A0 (en) | Histone demethylase inhibitors | |
| DK3481826T3 (da) | Tyrosinkinaseinhibitorer | |
| EP3628374C0 (en) | BCL-3 INHIBITORS | |
| EP3525786A4 (en) | KDM5 INHIBITORS | |
| DK3322724T3 (da) | Il-26 inhibitorer | |
| EP3525785A4 (en) | KDM5 INHIBITORS |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B07D | Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette] |
Free format text: DE ACORDO COM O ARTIGO 229-C DA LEI NO 10196/2001, QUE MODIFICOU A LEI NO 9279/96, A CONCESSAO DA PATENTE ESTA CONDICIONADA A ANUENCIA PREVIA DA ANVISA. CONSIDERANDO A APROVACAO DOS TERMOS DO PARECER NO 337/PGF/EA/2010, BEM COMO A PORTARIA INTERMINISTERIAL NO 1065 DE 24/05/2012, ENCAMINHA-SE O PRESENTE PEDIDO PARA AS PROVIDENCIAS CABIVEIS. |
|
| B07E | Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette] | ||
| B06U | Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette] | ||
| B11B | Dismissal acc. art. 36, par 1 of ipl - no reply within 90 days to fullfil the necessary requirements |